Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
OBJECTIVE
Evidence of the long-term efficacy and safety of alfuzosin treatment for LUTS indicative of BPH was examined.


METHODS
An English literature search of MEDLINE, PubMed and proceedings from scientific meetings from 1974 to 2004 was done. Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, lower urinary tract symptoms, complications or adverse events, sexual, retention and cardiovascular.


RESULTS
Currently alpha(1)-adrenergic receptor blocking agents are first line treatment for BPH. Although all alpha-blocking compounds show similar levels of efficacy for LUTS treatment, newer agents such as alfuzosin tend to demonstrate improved selectivity for the prostate and bladder with few vasodilatory effects and they have tolerability advantages over older alpha-blocking compounds. Immediate, sustained and newer extended release alfuzosin formulations significantly improve LUTS indicative of BPH but extended release alfuzosin may be more convenient to administer and it tends to show better vasodilatory tolerability than the older immediate release formulation.


CONCLUSIONS
When used to treat BPH, alfuzosin provides symptom relief, decreased residual post-void urine volume and a decreased risk of acute urinary retention, which are maintained during long-term use. Most vasodilatory side effects occur early in treatment and they become less frequent thereafter. Patient quality of life also improves with maximal improvements observed after 12 months of treatment. Continued study will further clarify the physiological, clinical and personal benefits produced by alfuzosin when used for the management of LUTS indicative of BPH.
McVary
Kevin T
KT
Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. k-mcvary@northwestern.edu
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D011799:Quinazolines / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin